Abstract 1 BACKGROUND: The transfer of pathogenic immunoglobulin G antibodies from mother 2 to fetus is a critical step in the pathophysiology of alloimmune and autoimmune 3 diseases of the fetus and neonate. Immunoglobulin G transfer across the human 4 placenta to the fetus is mediated by the neonatal Fc receptor, and blockade of the 5 neonatal Fc receptor may provide a therapeutic strategy to prevent or minimize 6 pathological events associated with immune-mediated diseases of pregnancy. M281 is 7 a fully human, aglycosylated monoclonal immunoglobulin G1 anti-neonatal Fc receptor 8 antibody that has been shown to block the neonatal Fc receptor with high affinity in 9 nonclinical studies and in a phase 1 study in healthy volunteers. µg/mL or 300 µg/mL of M281. Concentrations of adalimumab and M281 in sample 1 aliquots from maternal and fetal circuits were analyzed using a sandwich enzyme-linked 2 immunosorbent assay and Meso Scale Discovery assay, respectively. 3
RESULTS:
In primary human villous trophoblasts, the saturation of the neonatal Fc 4 receptor by M281 was observed within 30-60 minutes at 0.15-5.0 µg/mL suggesting 5 rapid blockade of neonatal Fc receptor in placental cells. The transfer rate of 6 adalimumab (0.23% ± 0.21%) across dually perfused human placental lobule was 7 significantly decreased by 10 µg/mL and 300 µg/mL of M281 to 0.07 ± 0.01% and 0.06 8 ± 0.01%, respectively. Furthermore, the transfer rate of M281 was 0.002% ± 0.02%, 9 approximately 100-fold lower than that of adalimumab. Alloimmune and autoimmune diseases of the fetus and newborn result from maternal 2 development of potent pathogenic immunoglobulin G (IgG) antibodies that are 3 transferred from mother to fetus. 1 For example, hemolytic disease of the fetus and 4 newborn, fetal neonatal autoimmune thrombocytopenia, and autoimmune congenital 5 heart block result from development of maternal IgG antibodies against fetal red blood 6 cell antigens, platelets, or the developing fetal AV node, respectively. 1-3 With elevated 7 maternal titers and importantly, pathogenic IgG potency, the exposure of the fetus to 8 these alloantibodies or autoantibodies through the increasing placental transfer of IgG 9 from the second to third trimester results in damage to fetal tissues and disease 10 development. 4,5 11
The neonatal Fc receptor (FcRn) mediates the passage of IgG from mother to fetus in 12 addition to maintaining the long half-life of IgG by IgG recycling in vascular endothelial 13 cells. 6 These mechanisms suggest that an inhibitor of FcRn-IgG interaction may prevent 14 or minimize gestational transfer of pathogenic IgG from mother to fetus as well as 15 decrease pathogenic antibody titers in maternal circulation. M281 is a monoclonal 16 anti-FcRn antibody that binds with high affinity to the IgG binding site on FcRn and 17 blocks IgG binding to FcRn. In a phase 1 normal healthy volunteer study, M281 was 18 observed to rapidly saturate systemic FcRn upon intravenous administration and 19 decrease circulating IgG consistent with inhibition of IgG recycling. 7 M A N U S C R I P T SMFM-FT-19-21  M281 inhibits IgG transplacental transfer   Page 7 The aims of the current study were to determine the potential of M281 to inhibit 1 transplacental IgG transfer using adalimumab as a representative IgG molecule and to 2 determine whether M281, itself, is transferred across the human placenta using the 3 dually perfused human placental model. 4 in the dark with a VT645-labeled M281 for binding to cell-associated, unoccupied FcRn. 9
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Cells were washed in ice-cold buffer and analyzed for geometric mean fluorescence 10 index of cell-associated VT645-labeled M281. M281 label in cells incubated with media 11 alone represented the measure of 100% unoccupied receptors. Full FcRn saturation 12 was defined as <10% unoccupied receptors. 13
Placental perfusion studies 14
The transfer of test compounds M281 and adalimumab from the maternal-to-fetal 15 circulation was studied using the ex vivo technique of dual perfusion of placental lobule 16 as previously described by Nanovskaya et al. [8] [9] [10] Briefly, each placenta was examined 17 for tears, and 2 chorionic vessels (1 artery and 1 vein) supplying a single intact 18 peripheral cotyledon were cannulated with 3F and 5F umbilical catheters, respectively. 19
The cotyledon was trimmed and placed in the perfusion chamber with the maternal 20 circuits was maintained at 3.0 and 12 mL/min, respectively. The maternal perfusate was 1 equilibrated with a gas mixture made of 95% oxygen/5% carbon dioxide, and the fetal 2 perfusate with a mixture of 95% nitrogen/5% carbon dioxide. recirculation of the perfusate. The perfusion was terminated, and experiment was not 7 initiated if one or more of the following criteria were observed during control period: fetal 8 volume loss of >2 mL/h, and/or a difference between partial pressure of oxygen in fetal 9 vein and artery less than 60 mm Hg. 10
Following the control period, maternal and fetal perfusates were replaced with fresh 11 medium containing 3 mg/mL of bovine serum albumin. Experimental period was 12 performed using closed-closed configuration of the system, ie, with recirculation of the 13 perfusates. The experimental period was initiated after addition to the maternal reservoir 14 of tests substances. The nonionizable, lipophilic marker compound antipyrine (100 15 µg/mL) was co-transfused with test substance(s) to assure that all studies maintained 16 an adequate level of perfusion overlap, ie, transfer of antipyrine to the fetal circuit within 17 120 minutes was >35%. 11,12 18
In a first set of experiments, the extent of M281 transfer (concentrations between 300 19 and 20,000 µg/µL) across dually perfused human placental lobule was carried out for 4 20 or 6 hours. In a second set of experiments, the extent of transplacental transfer of 21 adalimumab (270 µg/mL) during 6 hours of perfusion 13 experiments was then performed wherein the inhibitory effect of M281 on the 1 transplacental transfer of adalimumab (270 µg/mL) was studied. In these experiments, 2 M281 concentrations of 10 and 300 µg/mL were investigated. These concentrations of 3 M281 represent serum levels of M281 observed in the phase 1 study of M281. 7 4 Samples from maternal artery and fetal vein (in 0.5 mL aliquots) were taken at 0, 30, 60, 5 120, 180, 240, 270, 300, 330, and 360 minutes during the experimental period and 6 frozen at -80°C until analysis. 7
Sample and data analysis 8
Quantitation of the antipyrine 9
Concentrations of antipyrine in maternal and fetal aliquots were measured using a 10 modified high performance liquid chromatography (HPLC) method previously described 11 by Mørck. 14 Briefly, protein was precipitated by addition of 200 µL of ice-cold acetonitrile 12 containing 10 µL/mL of internal standard phenacetin to each 200 µL sample. Samples 13 were centrifuged at 8000 rpm, and supernatants were run on an Agilent 1200 HPLC 14 system equipped with a G1315D DAD detector (Agilent Technologies, Santa Clara, 15 CA). Antipyrine was analyzed using an HPLC method with a lower limit of quantification 16 of 5 µg/mL. The HPLC analysis was performed at room temperature (22°-25°C) using a 17 reverse-phase C18 based column (Waters Atlantis T3, Atlantis T3 Column, 100Å, 3 µm, M281 idiotype detection antibody, followed by detection with Sulfo-Tag Streptavidin, and 1 analyzed on a Meso QuickPlex SQ 120 (Meso Scale Discovery, Rockville, MD). Data 2 were analyzed using MSD Workbench 4.0 (Meso Scale Discovery). 3
Fetal transfer rate 4
The fetal transfer rate (FTR) for each test substance (adalimumab, M281, or antipyrine) 5 was calculated as "100 x concentration of the test substance in the fetal circuit at the 6 end of the experimental period/concentration of the test substance in the maternal 7 circuit at the start of the experimental period". 8
Statistical analysis 9
A linear mixed effects model was used for analysis of all the experimental data with 10 random terms for both slope and intercept for each donor identification to account for 11 the correlation among measurements from the same donor/placental perfusion 12 experiment. Two main experimental groups were considered for this analysis: 
Transfer of test compounds across dually perfused human placental lobule. 1
Very low concentrations of M281 were detected in the fetal circuit throughout the 2 experimental period (Figure 2, Table 1) . The low amount of M281 transferred to the 3 fetal circuit increased steadily and in proportion with the concentration added to the 4 maternal circuit suggesting transfer by a non-saturable process. The average FTR of 5 M281 across different concentrations tested (300 µg/mL, 3000 µg/mL, 20,000 µg/mL) 6 was 0.002% ± 0.002% (Table 1) indicated an extremely low transfer rate even at the 7 highest concentration tested. 8
The transfer of the representative IgG (adalimumab) showed an initial decline in 9 concentration in the maternal circulation during initial 30 minutes, which can be 10 attributed to the distribution of the adalimumab in the perfused lobule. Adalimumab 11 appeared in the fetal circuit after 60 minutes and its transfer increased substantially 12 through the end of the experimental period (Figure 3) . At the end of 6 hours of 13 perfusion, the average FTR of adalimumab was 0.23% ± 0.21% (range, 0.05%-0.65%, 14 n=8, Table 2 ). 15
The effect of M281 on transplacental transfer of adalimumab 16
In the presence of M281, detectable transfer of adalimumab across the placental lobule 17 was delayed (>120 minutes vs >60 minutes) and fetal transfer rates were decreased 18 irrespective of the concentrations of M281 tested (Figure 4, Table 2 ). However, the The FTR of the representative IgG, adalimumab (0.23% ± 0.21%), in the absence of 14 M281 was similar to previously reported IgG transfer rates (0.08-0.5%) in this 15 model. 13, [23] [24] [25] The high variability in the extent of adalimumab transfer across the 16 placenta lobule may be explained in part by factors such as individual variability in IgG 17 uptake by pinocytosis, expression of IgG-binding Fc gamma receptors, or vesicular 18
trafficking. No association was found between FcRn expression and adalimumab FTR 19
in these studies (data not shown). Page 17 In the presence of M281, the adalimumab transfer rate decreased by approximately 3-1 to 4-fold ( Table 2 ) and remained at 0.06-0.07%, irrespective of the M281 concentration 2 tested (10 or 300 µg/mL). It should be noted that the diminished transfer rate of 3 adalimumab in the presence of M281 is similar to the previously reported transfer rate 4 for immunoglobulin A, 26 an immunoglobulin isotype known to transfer extremely poorly 5 across the human placenta in pregnancy. Furthermore, IVIg which at high 6 concentrations acts as a competitive inhibitor at the FcRn IgG binding site was used as 7 a positive control. The inhibitory effect of 6700 µg/mL of IVIg on adalimumab transfer to 8 the fetal circuit (FTR 0.07 ± 0.03%, Supplementary Materials) was similar to the 9 inhibitory effect of M281 at 10 ug/mL (FTR 0.07 ± 0.01%, Table 2 ). 10
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SMFM-FT-19-21 M281 inhibits IgG transplacental transfer
These data suggest that the transfer of IgG in the presence of M281 may be negligible 11 in vivo. Both 10 and 300 µg/mL of M281 resulted in similar decreases in adalimumab 12 transfer rates suggesting that the inhibitory activity of M281 on IgG transport was 13 saturated. These ex vivo model results are consistent with the rapid uptake and 14 receptor occupancy of FcRn by M281 in HVTs at concentrations as low as 5 µg/mL. 15
Since concentrations of M281 above 10 µg/mL were maintained along with FcRn 16 receptor occupancy with weekly 30 mg/kg dosing of healthy volunteers in the phase 1 17 study, a sustained blockade of IgG transfer across the human placenta may be 18 achievable in clinical studies. 7 19
The transfer rate of M281 itself across the perfused placenta lobule was 20 0.002 ± 0.002%, which is nearly 100-fold lower than the transfer rate for the 21 representative IgG, adalimumab alone. This low transfer rate of M281 is unlikely to Adalimumab (270 µg/mL) and control antipyrine (100 µg/mL) were added to the 3 maternal circuit at t = 0 and measured in both maternal and fetal circuits during the 4 experimental period. Fetal transfer of adalimumab increased significantly after 60 5 minutes. Successful, consistent perfusion overlap was achieved in these studies as 6 antipyrine (inset) transfer rapidly reached equilibrium between maternal and fetal 7 circuits. Data are shown as mean ± standard deviation (n=8). 8
FIGURE 4 9
Placental transfer of adalimumab is inhibited in the presence of M281 10 Adalimumab (270 µg/mL), M281 (10 µg/mL, n=3 or 300 µg/mL, n=5) and control 11 antipyrine (100 µg/mL) were added to the maternal circuit at t = 0 and measured in both 12 maternal and fetal circuits over the experimental period. M281, irrespective of 13 concentration tested, significantly decreased adalimumab transfer compared with its 14 transfer in the absence of M281 (Figure 3 ).Data are shown as mean ± standard 15 deviation. One study was terminated early at 3 hours. ND, not determined; below limit of quantitation; SD, standard deviation. One study was terminated early at 5.5 hours. SD, standard deviation.
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